Early Infection Detection Improves Breast Reconstruction Outcomes | News-Medical.net

One in eight women in the United States will develop breast cancer in her lifetime, and roughly half will undergo mastectomy. For many, breast reconstruction with implants offers a path toward restoring body image and quality of life. However, a significant challenge remains: the risk of post-surgical infection, often requiring intravenous antibiotics, implant removal, and further surgeries. Now, researchers are reporting a potential breakthrough – a new tool to detect these infections weeks before symptoms appear, potentially allowing for preemptive treatment and improved outcomes.

A team at Washington University School of Medicine in St. Louis has identified specific biomarkers in fluid drained from breasts undergoing reconstruction that signal an impending infection. This discovery, published online and slated for the February 16 print edition of the Journal of Clinical Investigation, offers a significant advancement over current diagnostic methods, which rely on visible signs like redness and inflammation – indicators that can be delayed and mimic normal post-operative reactions.

Early Detection: A Molecular Signature of Infection

The research, led by Jeffrey P. Henderson, MD, PhD, a professor in the John T. Milliken Department of Medicine at WashU Medicine, centers on the concept of metabolomics – the study of small molecules, or metabolites, produced during cellular processes. These metabolites can act as indicators of infection, reflecting both the body’s immune response and the metabolic activity of invading pathogens. By analyzing changes in metabolite levels, the researchers aimed to identify patterns characteristic of infection, enabling earlier diagnosis.

The study involved collecting fluid samples from 50 patients undergoing breast reconstruction following mastectomy at various routine follow-up visits. Researchers then compared samples from patients who subsequently developed infections with those who remained infection-free. This analysis revealed specific metabolites significantly associated with infection, appearing days to weeks before clinical symptoms manifested. Importantly, the presence of certain metabolites also correlated with more severe infections, potentially guiding treatment intensity.

“The ability to identify with a molecular signature early on that a patient will go on to have an infection opens up the possibility of surveillance as part of standard care,” explained Dr. Henderson. “This has the potential to enable earlier treatment that would be far more effective – and potentially curative – in patients who would otherwise progress to prolonged courses of treatment and surgery, or even implant removal and reconstructive failure.”

From Clinical Observation to Metabolomic Analysis

The impetus for this research stemmed from observations made by Margaret A. Olsen, PhD, a retired professor of medicine specializing in hospital infections. Dr. Olsen noticed a concerningly high rate of infection among U.S. Patients undergoing implant-based breast reconstruction. This prompted a conversation with WashU Medicine plastic surgeons, who expressed a need for a simple, definitive test to identify infection early.

The researchers emphasize that infections following breast reconstruction don’t follow a uniform timeline. A study analyzing data from over 1,000 patients undergoing two-stage implant-based reconstruction at Seoul National University Hospital (2015-2020) revealed distinct patterns. Infections after the first stage (tissue expander insertion) exhibited a bimodal distribution – meaning they occurred in two distinct peaks of time – while infections after the second stage (expander exchange) followed a unimodal pattern, peaking at a single point in time. Risk factors also differed between stages. Axillary lymph node dissection (ALND) was linked to early infections after the first stage, while both ALND and obesity were associated with late infections. After the second stage, obesity, postmastectomy radiotherapy, a history of expander infection, ALND, and the use of textured implants were identified as independent risk factors.

Implications for Patient Care and Antibiotic Stewardship

The potential applications of this new diagnostic tool are far-reaching. Researchers envision a point-of-care test that could be administered during routine post-operative visits. A positive result could trigger preemptive antibiotic treatment, potentially preventing the infection from taking hold. Conversely, a negative result could help avoid unnecessary antibiotic use, a crucial step in combating the growing threat of antibiotic resistance.

“If the test is positive, antibiotics can be started preemptively in these select patients to thwart infection,” said Terence M. Myckatyn, MD, a professor of surgery at WashU Medicine specializing in breast cancer reconstruction. “And perhaps just as important, we would not give antibiotics to those with a negative test, thereby adhering to a thoughtful approach for antibiotic stewardship.”

Justin M. Sacks, MD, director of the Division of Plastic and Reconstructive Surgery at WashU Medicine, highlighted the significance of the study’s clinical grounding. “Originating from clinical intuition and validated through a clinical study, the evidence in this paper now supports proactive, targeted interventions to predict and address infections before they become clinically significant,” he stated. “Such interventions can substantially reduce the burden of complications, implant loss and reconstructive failures in these patients.”

The research team is currently planning further studies to validate these findings and pave the way for the development and clinical testing of a diagnostic tool. Beyond breast reconstruction, the broader insights gained from this metabolomic analysis could potentially be applied to identify and manage infections following other surgical procedures, revealing new targets for therapeutic intervention.

As Dr. Myckatyn concluded, “To be able to identify biomarkers that can portend an infection days before it develops is huge.”